Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 21.96 is in line with its 5-year average of 20.51, around the middle of its 5-year range (14.25–32.06).
As of the fiscal period ended Tuesday, June 30, 2026. 1.08% below its 12-month average of 22.20.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 21.96.
QUICK RATIO (ACID-TEST)
21.96
QUICK RATIO (ACID-TEST) AVG TTM
22.20
QUICK RATIO (ACID-TEST) AVG 3Y
20.46
QUICK RATIO (ACID-TEST) AVG 5Y
20.51
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-1.08%
CURRENT VS 3Y AVG
+7.35%
CURRENT VS 5Y AVG
+7.07%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+555.53%
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$218.30M
Quick Ratio (Acid-Test)
21.96
TTM Avg
22.20
3Y Avg
20.46
5Y Avg
20.51
Market Cap
$216.91M
Quick Ratio (Acid-Test)
4.07
TTM Avg
3.65
3Y Avg
6.88
5Y Avg
10.38
Market Cap
$220.93M
Quick Ratio (Acid-Test)
5.31
TTM Avg
10.41
3Y Avg
9.80
5Y Avg
12.54
Market Cap
$215.07M
Quick Ratio (Acid-Test)
344.31
TTM Avg
177.51
3Y Avg
95.13
5Y Avg
76.52
Market Cap
$214.46M
Quick Ratio (Acid-Test)
20.05
TTM Avg
17.55
3Y Avg
12.54
5Y Avg
12.54
Market Cap
$214.24M
Quick Ratio (Acid-Test)
5.13
TTM Avg
3.45
3Y Avg
2.59
5Y Avg
2.27
Market Cap
$225.24M
Quick Ratio (Acid-Test)
10.14
TTM Avg
15.36
3Y Avg
19.42
5Y Avg
27.25
Market Cap
$210.98M
Quick Ratio (Acid-Test)
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$210.41M
Quick Ratio (Acid-Test)
10.89
TTM Avg
11.84
3Y Avg
8.89
5Y Avg
15.32
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $218.30M | 21.96 | 22.20 | 20.46 | 20.51 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 4.07 | 3.65 | 6.88 | 10.38 |
| Profound Medical Corp. (PROF)vs › | $220.93M | 5.31 | 10.41 | 9.80 | 12.54 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 344.31 | 177.51 | 95.13 | 76.52 |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | 20.05 | 17.55 | 12.54 | 12.54 |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 5.13 | 3.45 | 2.59 | 2.27 |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | 10.14 | 15.36 | 19.42 | 27.25 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | 5.36 | 6.17 | 11.50 | 11.99 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 10.89 | 11.84 | 8.89 | 15.32 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 5.72 | 5.91 | 5.85 | 7.15 |
Quick Ratio
21.96
Excludes inventory
Current Ratio
21.96
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 21.96 |
| 2026-03-31 | 22.62 |
| 2025-12-31 | 15.45 |
| 2025-09-30 | 29.86 |
| 2025-06-30 | 21.11 |
| 2025-03-31 | 19.29 |
| 2024-12-31 | 21.45 |
| 2024-09-30 | 19.03 |
| 2024-06-30 | 20.37 |
| 2024-03-31 | 24.74 |
| 2023-12-31 | 14.25 |
| 2023-09-30 | 18.23 |
| 2023-06-30 | 20.77 |
| 2023-03-31 | 23.43 |
| 2022-12-31 | 17.27 |
| 2022-09-30 | 21.33 |
| 2022-06-30 | 14.39 |
| 2022-03-31 | 19.85 |
| 2021-12-31 | 21.23 |
| 2021-09-30 | 20.52 |
| 2021-06-30 | 32.06 |
| 2021-03-31 | 28.60 |
| 2020-12-31 | 37.27 |
| 2020-09-30 | 19.99 |
| 2020-06-30 | 17.91 |
| 2020-03-31 | 6.40 |
| 2019-12-31 | 1.99 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
